Literature DB >> 17142121

A novel interstitial deletion in Xq25, identified by array-CGH in a patient with Lowe syndrome.

Maria Addis1, Cristiana Meloni, Rita Congiu, Simona Santaniello, Francesco Emma, Orsetta Zuffardi, Roberto Ciccone, Antonio Cao, Maria Antonietta Melis, Milena Cau.   

Abstract

The oculocerebrorenal syndrome of Lowe (OCRL) (MIM:309000) is an X-linked multisystemic disorder affecting the eyes, nervous system and kidneys due to mutations in OCRL1 gene. The gene contains 24 exons, and encodes a 105kDa phosphatydylinositol 4,5-biphosphate [PtdIns(4,5)P(2)] 5-phosphatase localized primarily in the trans-Golgi network and the lysosomes. The large majority of the OCRL1 mutations producing Lowe syndrome are either missense mutations localized mainly in the catalytic domain or non-sense/frameshift mutations resulting in truncated proteins. Rarely, in about 6% of the cases, the disease results from large gene deletions occurring in the 5' part of the gene. Here we report a new case of a patient with Lowe syndrome due to a deletion of about 4Mb, encompassing the OCRL1 gene, detected by PCR and CGH array. The mother was carrier of the same deletion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17142121     DOI: 10.1016/j.ejmg.2006.10.003

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  5 in total

1.  A novel and de novo deletion in the OCRL1 gene associated with a severe form of Lowe syndrome.

Authors:  Ramón Peces; Carlos Peces; Erika de Sousa; Cristina Vega; Rafael Selgas; Julián Nevado
Journal:  Int Urol Nephrol       Date:  2012-07-21       Impact factor: 2.370

2.  Characterization of 28 novel patients expands the mutational and phenotypic spectrum of Lowe syndrome.

Authors:  Florian Recker; Marcin Zaniew; Detlef Böckenhauer; Nunzia Miglietti; Arend Bökenkamp; Anna Moczulska; Anna Rogowska-Kalisz; Guido Laube; Valerie Said-Conti; Belde Kasap-Demir; Anna Niemirska; Mieczysław Litwin; Grzegorz Siteń; Krystyna H Chrzanowska; Małgorzata Krajewska-Walasek; Sidharth K Sethi; Velibor Tasic; Franca Anglani; Maria Addis; Anna Wasilewska; Maria Szczepańska; Krzysztof Pawlaczyk; Przemysław Sikora; Michael Ludwig
Journal:  Pediatr Nephrol       Date:  2014-12-06       Impact factor: 3.714

3.  Exome-first approach identified a novel gloss deletion associated with Lowe syndrome.

Authors:  Miki Watanabe; Ryuji Nakagawa; Tomohiro Kohmoto; Takuya Naruto; Ken-Ichi Suga; Aya Goji; Hideaki Horikawa; Kiyoshi Masuda; Shoji Kagami; Issei Imoto
Journal:  Hum Genome Var       Date:  2016-11-10

4.  Modeling the neuropsychiatric manifestations of Lowe syndrome using induced pluripotent stem cells: defective F-actin polymerization and WAVE-1 expression in neuronal cells.

Authors:  Jesse Barnes; Franklin Salas; Ryan Mokhtari; Hedwig Dolstra; Erika Pedrosa; Herbert M Lachman
Journal:  Mol Autism       Date:  2018-08-15       Impact factor: 7.509

5.  Whole-genome sequencing revealed an interstitial deletion encompassing OCRL and SMARCA1 gene in a patient with Lowe syndrome.

Authors:  Bixia Zheng; Qiuxia Chen; Chunli Wang; Wei Zhou; Ying Chen; Guixia Ding; Zhanjun Jia; Aihua Zhang; SongMing Huang
Journal:  Mol Genet Genomic Med       Date:  2019-08-03       Impact factor: 2.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.